Company intelligence / Profile preview

Eyegenex

San Diego / San Francisco* [2], California/San Diego* or San Francisco* [see note below], United Stateseyegenex.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Eyegenex has demonstrated efficacy in reducing visual loss in animal models for glaucoma and diabetic retinopathy. Non-human primate studies are pending, with first-in-human clinical trials expected to begin in 2025. The company is also developing a biosynthetic artificial cornea derived from collagen, with early successes reported in preclinical studies.[1][5]

Therapeutic areas: Ophthalmology
Modalities: Gene therapyPeptide therapyBiosynthetic tissue (artificial cornea)Considering stem cell therapies[5][7]
Industry: Biotech

Partnerships

University of Colorado Anschutz Medical Campus (licensing partner)[7]NuFund Venture Group (lead investor/advisor)[4]

Beyond the preview

Go deeper on Eyegenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyegenex.

Explore the full profile